Monosomy 3 Influences Epithelial-Mesenchymal Transition Gene Expression in Uveal Melanoma Patients; Consequences for Liquid Biopsy.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Case-Control Studies
Chromosome Deletion
Chromosomes, Human, Pair 3
/ genetics
DNA, Neoplasm
/ analysis
Epithelial-Mesenchymal Transition
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Liquid Biopsy
Male
Melanoma
/ genetics
Middle Aged
Neoplastic Cells, Circulating
/ metabolism
Prognosis
Uveal Neoplasms
/ genetics
circulating tumor DNA
circulating tumor cells
epithelial-mesenchymal transition
gene expression profiling
uveal melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
31
10
2020
revised:
13
12
2020
accepted:
14
12
2020
entrez:
22
12
2020
pubmed:
23
12
2020
medline:
19
3
2021
Statut:
epublish
Résumé
Despite outstanding advances in diagnosis and the treatment of primary uveal melanoma (UM), nearly 50% of UM patients develop metastases via hematogenous dissemination, driven by the epithelial-mesenchymal transition (EMT). Despite the failure in UM to date, a liquid biopsy may offer a feasible non-invasive approach for monitoring metastatic disease progression and addressing protracted dormancy. To detect circulating tumor cells (CTCs) in UM patients, we evaluated the mRNA expression of EMT-associated transcription factors in CD45-depleted blood fraction, using qRT-PCR. ddPCR was employed to assess UM-specific
Identifiants
pubmed: 33348918
pii: ijms21249651
doi: 10.3390/ijms21249651
pmc: PMC7767066
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-17-0369
Organisme : KEGA
ID : 016UK-4/2018
Organisme : The European Regional Development Fund
ID : No. ERDF ITMS: 26240220044.
Références
Cancer. 2005 Mar 1;103(5):1000-7
pubmed: 15651058
PLoS One. 2015 Mar 12;10(3):e0116371
pubmed: 25764247
Ophthalmology. 2000 Aug;107(8):1443-9
pubmed: 10919885
Br J Ophthalmol. 2003 May;87(5):629-32
pubmed: 12714409
Biol Chem. 2002 May;383(5):725-37
pubmed: 12108537
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
Oncol Res. 2016;24(3):197-204
pubmed: 27458101
Oncogene. 2005 Mar 31;24(14):2375-85
pubmed: 15674322
Sci Rep. 2019 Nov 20;9(1):17178
pubmed: 31748560
Oncology (Williston Park). 2016 Jan;30(1):29-32, 34-43, 48
pubmed: 26791842
Nat Cell Biol. 2000 Feb;2(2):84-9
pubmed: 10655587
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):658-65
pubmed: 19797220
JCO Precis Oncol. 2018 May 17;2:
pubmed: 32913999
Ophthalmology. 2011 Feb;118(2):396-401
pubmed: 20869116
Graefes Arch Clin Exp Ophthalmol. 2012 Jun;250(6):887-95
pubmed: 21881845
Sci Rep. 2017 Dec;7(1):45
pubmed: 28246385
J Pathol. 2020 Apr;250(4):420-439
pubmed: 31960425
Sci Rep. 2019 Feb 28;9(1):2990
pubmed: 30816227
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
Clin Cancer Res. 2012 Jul 15;18(14):3934-41
pubmed: 22645051
Biomed Res Int. 2018 May 31;2018:4060728
pubmed: 29955600
Immunity. 2012 Feb 24;36(2):201-14
pubmed: 22326581
Mol Cell. 2001 Jun;7(6):1267-78
pubmed: 11430829
Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794630
pubmed: 30181785
Int J Cancer. 2019 Sep 1;145(5):1395-1407
pubmed: 30828790
Oncotarget. 2017 May 19;8(42):73219-73239
pubmed: 29069865
Eye (Lond). 2007 Jun;21(6):752-9
pubmed: 16575415
Int J Cancer. 2014 Mar 1;134(5):1207-13
pubmed: 23934701
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33008022
Clin Cancer Res. 2012 Jul 1;18(13):3552-61
pubmed: 22550165
BMC Cancer. 2016 Feb 19;16:127
pubmed: 26896000
Cancer Med. 2019 Jun;8(6):2717-2729
pubmed: 30950241
Sci Rep. 2017 Apr 27;7(1):1220
pubmed: 28450698
Clin Ophthalmol. 2013;7:1669-82
pubmed: 24003303
Med Oncol. 2014 Jul;31(7):64
pubmed: 24930007
Methods Mol Biol. 2014;1102:427-40
pubmed: 24258991
Indian J Ophthalmol. 2015 Feb;63(2):93-102
pubmed: 25827538
Front Immunol. 2018 Jan 10;8:1911
pubmed: 29375561
Mol Cell. 2006 Apr 21;22(2):231-43
pubmed: 16630892
Int J Cancer. 2012 Feb 15;130(4):808-16
pubmed: 21387303
Nat Commun. 2019 Nov 11;10(1):5115
pubmed: 31712603
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462507
Acta Ophthalmol. 2015 Feb;93(1):59-66
pubmed: 25613126
Anticancer Res. 2019 Apr;39(4):1829-1837
pubmed: 30952723
Cancer Res. 2011 Feb 1;71(3):666-74
pubmed: 21135111
J Biochem. 2018 May 1;163(5):399-412
pubmed: 29462330
J Dermatol Sci. 2018 Sep;91(3):317-324
pubmed: 30025750
Oncol Rep. 2013 Dec;30(6):2859-63
pubmed: 24100634
FASEB J. 2017 Sep;31(9):3922-3933
pubmed: 28522595
Ophthalmology. 2012 Aug;119(8):1596-603
pubmed: 22521086
EBioMedicine. 2015 Sep 18;2(11):1821-6
pubmed: 26870807
Oncoimmunology. 2014 Oct 31;8(10):e947169
pubmed: 31646061
Cancers (Basel). 2019 Aug 02;11(8):
pubmed: 31382450
Cancer Med. 2019 Jul;8(7):3544-3552
pubmed: 31090199
Mol Vis. 2015 Aug 25;21:919-29
pubmed: 26321866
Cancer Med. 2013 Apr;2(2):208-15
pubmed: 23634288
Cell. 2004 Jun 25;117(7):927-39
pubmed: 15210113
Curr Mol Med. 2010 Jun;10(4):419-29
pubmed: 20455858
Br J Cancer. 2014 Sep 23;111(7):1373-80
pubmed: 25058347
J Pathol. 2016 Mar;238(4):485-8
pubmed: 26576691
Int J Ophthalmol. 2016 Dec 18;9(12):1701-1712
pubmed: 28003967
Int J Mol Sci. 2020 Aug 03;21(15):
pubmed: 32756477
Nat Genet. 2019 Jul;51(7):1123-1130
pubmed: 31253977
Int J Oncol. 2015 Oct;47(4):1177-88
pubmed: 26316068
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Dev Biol. 2015 May 1;401(1):143-51
pubmed: 25553982
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Nov;31(11):1523-7
pubmed: 26522362
PLoS One. 2014 Aug 28;9(8):e105372
pubmed: 25166211
Oncol Rep. 2015 Jul;34(1):295-301
pubmed: 25955651
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6
pubmed: 16505010
Tumour Biol. 2017 Jul;39(7):1010428317711098
pubmed: 28718370
Cancer Res. 2006 May 1;66(9):4602-9
pubmed: 16651410
Virchows Arch. 2003 Dec;443(6):741-4
pubmed: 14513377